Skip to main
OCGN
OCGN logo

Ocugen, Inc. (OCGN) Stock Forecast & Price Target

Ocugen, Inc. (OCGN) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ocugen Inc. is focused on innovative solutions for retinal diseases through its modifier gene therapy platform, which addresses significant unmet medical needs such as inherited retinal diseases (IRDs) and other complex conditions. The company's ongoing phase I/II study of OCU400 shows promising potential due to its strong efficacy and safety profile, which could lead to positive outcomes in clinical endpoints. Additionally, collaboration agreements and possibilities for mergers and acquisitions may enhance Ocugen's market position and financial growth, paving the way for a favorable outlook in the biotech sector.

Bears say

Ocugen Inc. faces a negative outlook due to its inability to secure essential investment, which it attributes to poor market conditions and stringent Nasdaq compliance timelines. The company's ongoing development of therapies for retinal diseases is overshadowed by the potential emergence of new treatment methods that could render Ocugen's offerings non-competitive or obsolete. Additionally, despite the company's focus on innovative gene and cell therapies, the current financial environment poses a significant challenge to its growth prospects, raising concerns about the sustainability of its operations.

Ocugen, Inc. (OCGN) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocugen, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocugen, Inc. (OCGN) Forecast

Analysts have given Ocugen, Inc. (OCGN) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Ocugen, Inc. (OCGN) has a Strong Buy consensus rating as of Dec 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocugen, Inc. (OCGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.